Cart
sales@molnova.com
Abeprazan hydrochloride
CAS No. 1902954-87-3
Abeprazan hydrochloride( —— )
Catalog No. M32767 CAS No. 1902954-87-3
Abeprazan hydrochloride (Fexuprazan hydrochloride) is an effective reversible potassium-competitive acid blocker with oral activity, inhibiting H+, K+ -atPase by competitive binding to potassium ions without acid activation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 143 | In Stock |
|
| 5MG | 226 | In Stock |
|
| 10MG | 335 | In Stock |
|
| 25MG | 522 | In Stock |
|
| 50MG | 707 | In Stock |
|
| 100MG | 888 | In Stock |
|
| 500MG | 1782 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAbeprazan hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionAbeprazan hydrochloride (Fexuprazan hydrochloride) is an effective reversible potassium-competitive acid blocker with oral activity, inhibiting H+, K+ -atPase by competitive binding to potassium ions without acid activation.
-
DescriptionAbeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases.
-
In VitroThe mechanism of action of Abeprazan hydrochloride is reversibly binding to H+, K+‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation.
-
In VivoAbeprazan hydrochloride (DWP14012 hydrochloride) inhibits acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion is equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models.
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetProton Pump
-
RecptorProton pump
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1902954-87-3
-
Formula Weight446.87
-
Molecular FormulaC19H18ClF3N2O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (55.94 mM; Ultrasonic )
-
SMILESCl.CNCc1cn(c(c1OC)-c1ccc(F)cc1F)S(=O)(=O)c1cccc(F)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sunwoo J, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018 Jul;48(2):206-218.?
molnova catalog
related products
-
Lansoprazole sodium
Lansoprazole sodium is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity which is widely used in the therapy of gastroesophageal reflux and peptic ulcer disease.
-
Vonoprazan Fumarate
Vonoprazan Fumurate, a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumurate inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5.
-
(R)-Tegoprazan
(R)-Tegoprazan (example 3), a benzimidazole derivative, is a potent kidney H+/K+-ATPase inhibitor with an IC50 of 98 nM of canine kidney Na+/K+-ATPase.
